LungLife AI's primary business segment revolves around the development and commercialization of diagnostic solutions for early lung cancer detection. This includes the LungLB® test, a blood-based assay designed to stratify cancerous and benign lung nodules identified through CT scans. The company collaborates with thoracic surgeons, pulmonologists, pathologists, and molecular biologists to refine and validate its diagnostic technologies. Research and development efforts focus on improving the sensitivity and specificity of liquid biopsy techniques, leveraging artificial intelligence and machine learning to enhance diagnostic accuracy. The goal is to provide clinicians with actionable insights for timely intervention, ultimately improving patient outcomes and reducing the burden of lung cancer.